Newsflash: Weight loss medication recently approved by the FDA. Find out all the details.

In current times where taking care of your health is fundamental, one of the leading indicators is weight. As it is known, obesity is a disease that can bring on silent side effects.

The Food and Drug Administration (FDA) has recently approved a weight loss medication, it is called Semaglutide, a major breakthrough in the market which can bring amazing benefits those who want to reduce waist size. This breakthrough is the newest pharmacological addition that can be found in the market and is approved for long term weight loss, the results have been revolutionary for the quality of life of many people. There are many options, in this article we will explore details of those options.

Related links (Ads):

The Obesity Epidemic

Obesity is a complex disease in which one has excessive body fat. It is not only an aesthetic issue. It is a medical issue that increases the risks of diseases and health issues such as cardiac diseases, diabetes, high blood pressure and certain types of cancer (1).

There are many reasons why people have such a hard time avoiding obesity. In general, obesity is a result of a combination of hereditary factors with the environment, personal diet and exercise options.

The positive side is that even a modest loss in weight can improve or prevent health issues related to obesity. Change in diet, an increased level in physical activity and changes in conduct can lead to weight loss. Prescription drugs and procedures to lose weight can be additional options to treat obesity.

Prescription Drugs

The FDA has approved certain drugs that can help reduce long term weight (2)

Most prescription weight loss drugs may decrease your appetite or increase your feelings of fullness. Some do noth. There are exceptions, like the ones that interfere with the absorption of fat.

New Approved Medication

For the first time since 2013, the FDA has approved a drug that can help reduce your weight called Wegovy (Semaglutide) (3).

According to the publication by the FDA, Wegovy is effective to «reduce chronic weight in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol), to be used in conjunction with a diet low in calories and an increase in physical activity».

It is an injection of semaglutida that is applied under the skin in weekly dosis which need to be increased gradually until reeaching 2.4 mg, which may help with weight loss, up to 12.4%. It is recommended in people whose Body Mass Index (BMI) is over 27 kg/m2.

What does the drug do?

According to the description by the FDA, this drug acts like human GLP-1, which regulates appetite and food consumption in the brain. Semaglutide treatment needs to be administered and monitored by a healthcare professional as it should be increased gradually over 16 to 20 weeks until the maximum dose of 2.4 mg is reached.

For its approbal, the FDA considered the results of four clinical trials of 28 weeks in more than 2,600 patients that received Wegovy. The average age of the participants was 46 and 74$ were women with an average weight of 231 pounds. By the end of the treatment they lost an average of 12.4% of their weight. Another sstudy included people over 55 on average with type 2 diabetes and average weight of 220 pounds of which 51% were women. In this case, participants lost 6.2% of their initial weight on average.

Side Effect

Wegovy is not a free pass to your organism and has several potential side effects which may include nausea, diarrhea, vomiting, constipation, abdonimal pain, headache, fatigue, dyspepsia (indigestion), dissyness, abdominal distension, burping, hipoglucemia (low blood sugars) in patients with type 2 diabetes, flatulence, gastroenteritis y gastroesophageal reflux disease.

Furthermore, this drug is contraindicated for patients with history (either personal or family) of medullary thyroid carcinoma, in patients with a rare disease called multiple endocrine neoplasia syndrome type 2 (MEN 2), or in people with an allergy to semaglutide or any other component of its formula. The therapy is expected to be available in late July in the United States, where obesity and overweight affect 70% of adults, and it is essential that a health professional evaluates and monitors the administration of this drug.

Obviously, investing in a drug to lose weight is more than recommended and can be an excellent decision, especially for health, to avoid any type of associated evil.

Related links (Ads):